Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 1 for:    miflapro
Previous Study | Return to List | Next Study

Micronized Purified Flavonoid- Fraction (MPFF) in the Management of Radiation Proctitis (MiFlaPRO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04335617
Recruitment Status : Recruiting
First Posted : April 6, 2020
Last Update Posted : November 3, 2020
Servier Affaires Médicales
Information provided by (Responsible Party):
Irmgard E Kronberger, MD, Medical University Innsbruck

Brief Summary:
national and multi-center trial for medical therapy of chronic radiation proctitis inducing anorectal bleedings

Condition or disease Intervention/treatment Phase
Proctitis Radiation Drug: MMPF (Micronized purified Flavonoid-Fraction) Other: Placebo Phase 3

Detailed Description:

Radiation proctitis is an inflammation of rectal mucosa, a complication following radiation therapy for cancers of the prostate, cervix, uterus, bladder and other malignancies in the pelvic area. Around 20 % of radiation patients develop radiation proctitis. There is a significant lack of trial treatments for radiation proctitis, even more, the studies often are small and single center designed or case series. In 2 recent reviews pointing out the management of radiation proctitis (2018 and 2016) a summary of current options in therapy according to current scientific knowledge is given. Unfortunately, these studies are about interventional options with the serious risk of complication. Only little data and lack of significance in smaller series on conservative strategies are given.

The goal of the trial is to implement a specific medication in the management and every grade of radiation proctitis - concomitant to eventual need of MMPF is described with potent anti-inflammatory mucosal capacity reducing bleeding, pain and urgency symptoms in patients with hemorrhoidal and/or postoperative symptoms. By using a placebo instead of comparative oral medications (with low evidence) this study might illustrate clinical significance of expected results as well as information on the natural history of radiation proctitis.

The goal of the study is to compare the number of necessary interventions required to stop bleeding in chronic radiation proctitis in patients receiving MMPF in comparison to patients in the control group receiving Placebo within 12 months of medical treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This is a multicenter, randomized, double-blind, placebo-controlled Phase III study.
Masking: Double (Participant, Investigator)
Masking Description: In this double blinded study Daflon and placebo are packed in the same manner, the blind is also protected by randomization. Only the principal investigator can break the blind in case of ethical or threatening patterns by contacting the sponsor and clinical research item.
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double Blind Placebo Controlled Trial of Micronized Purified Flavonoid- Fraction (MPFF) in the Management of Radiation Proctitis
Actual Study Start Date : February 26, 2020
Estimated Primary Completion Date : February 26, 2023
Estimated Study Completion Date : August 26, 2023

Arm Intervention/treatment
Experimental: Investigational
Patients receive MMPF 500mg for one year
Drug: MMPF (Micronized purified Flavonoid-Fraction)
500mg film-coated tablet, oral route, tablets should be taken at meal times. 4-day course of 6 tablets daily, followed by 4 tablets over the next 3 days followed by 2 tablets daily, one at midday and one in the evening

Placebo Comparator: Placebo
Patients receive Placebo for one year
Other: Placebo
4-day course of 6 tablets daily, followed by 4 tablets over the next 3 days followed by 2 tablets daily

Primary Outcome Measures :
  1. Number of necessary intervention [ Time Frame: Day 1- Day 360 ]
    Interventions to stop acute bleeding by chronic radiation proctitis: surgical, endoscopic or proctoscopic interventions

Secondary Outcome Measures :
  1. Quality of life of patients [ Time Frame: Day 0 Day 180 Day 360 ]
    Differences in quality of life of patients will be measured with evaluation of two questionnaires (EORTC QLQ C30 & PRT20). Higher scores mean a better quality of life.

  2. Blood samples [ Time Frame: Day 0-Day 360 ]
    Differences in serum hemoglobin, thrombocytes, coagulation parameters (quick/pt=prothrombin time)

  3. Stool [ Time Frame: Day 0-Day 360 ]
    Differences in calprotectin stool level

  4. Presence of histological alterations [ Time Frame: Day 0-Day 360 ]
    Differences in histological alterations (distortion of crypts, Inflammation of crypts, fibrosis and ectasia of vessels, cytokines)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • signed informed consent form
  • male and female patients
  • age ≥ 18 years
  • patients with diagnosis of radiation proctitis with macroscopic bleeding
  • end of radiotherapy ≥ 3 month = 90 days ago

Exclusion Criteria:

  • infectious proctitis
  • ulcerative proctitis (inflammatory bowel disease)
  • persons unable to understand the informed consent
  • persons, who are in dependent relationship with the study investigators or Sponsor
  • pregnant or lactating women
  • participation in an interventional study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04335617

Layout table for location contacts
Contact: Irmgard Kronberger, MD +43 512 504 ext 0
Contact: Marijana Ninkovic, MD +43 512 504 ext 0

Layout table for location information
Medizinische Universität Innsbruck Recruiting
Innsbruck, Tyrol, Austria, 6020
Contact: Irmgard E Kronberger, MD   
Krankenhaus der Stadt Dornbirn Not yet recruiting
Dornbirn, Austria, 6850
Contact: Clemens Obwegeser, Dr.         
Barmherzige Brüder Krankenhaus Graz Recruiting
Graz, Austria, 8020
Contact: Martin Mitteregger, Dr.         
Medizinische Universität Graz Recruiting
Graz, Austria, 8036
Contact: Martina Lemmerer, Dr.         
Universitätsklinikum Krems Recruiting
Krems, Austria, 3500
Contact: Stefan Sattler, Dr.         
Ordensklinikum Linz GmbH Elisabethinen Recruiting
Linz, Austria, 4020
Contact: Ulrike Enkner, Dr.         
Kepleruniversität Linz Recruiting
Linz, Austria, 4040
Contact: Günther Klimbacher, Dr.         
Universitätsklinikum Tulln Recruiting
Tulln, Austria, 3430
Contact: Alf-Dorian Binder, Dr.         
Salzkammergut Klinikum Vöcklabruck Recruiting
Vöcklabruck, Austria, 4840
Contact: Raimund Strouhal, Dr.         
Medizinische Universität Wien Recruiting
Wien, Austria, 1090
Contact: Stefan Riss, Assoc.-Prof.         
Krankenhaus Nord, Klinik Floridsdorf Recruiting
Wien, Austria, 1210
Contact: Zacaria Sow, Dr.         
Sponsors and Collaborators
Medical University Innsbruck
Servier Affaires Médicales
Layout table for additonal information
Responsible Party: Irmgard E Kronberger, MD, Principle Investigator, Medical University Innsbruck Identifier: NCT04335617    
Other Study ID Numbers: MiFlaPRO_2019
First Posted: April 6, 2020    Key Record Dates
Last Update Posted: November 3, 2020
Last Verified: October 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Gastrointestinal Diseases
Digestive System Diseases
Rectal Diseases
Intestinal Diseases